SAN
JOSE, Calif., Oct. 31,
2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa"
or the "Company") (NASDAQ: ANIX), a biotechnology company focused
on the treatment and prevention of cancer, today announced its
presentation at the Sidoti Micro-Cap Virtual Conference, taking
place November 13-14, 2024. Anixa
Chairman and CEO Dr. Amit Kumar will
present an overview of the Company and its clinical programs.
Conference details:
Presentation: Thursday,
November 14, 2024, at 1:00pm
ET
Presentation link: Click here to register;
available via Zoom
Conference registration: Available on the
conference website
1x1 meetings: Open to all investors upon conference
registration
Dr. Kumar stated, "We are pleased to present at this conference,
shortly after release of the most up-to-date data from our breast
cancer clinical trial, which will occur on November 8, 2024. We will also provide updates to
our CAR-T trial for recurrent and resistant ovarian cancer
patients. Both trials are producing very positive results,
exceeding all of our expectations, and we look forward to providing
an update."
About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the
treatment and prevention of cancer. Anixa's therapeutic portfolio
consists of an ovarian cancer immunotherapy program being developed
in collaboration with Moffitt Cancer Center, which uses a novel
type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T)
technology. The Company's vaccine portfolio includes vaccines being
developed in collaboration with Cleveland Clinic to treat and
prevent breast cancer and ovarian cancer, as well as additional
cancer vaccines to address many intractable cancers, including high
incidence malignancies in lung, colon, and prostate. These vaccine
technologies focus on immunizing against "retired" proteins that
have been found to be expressed in certain forms of cancer. Anixa's
unique business model of partnering with world-renowned research
institutions on all stages of development allows the Company to
continually examine emerging technologies in complementary fields
for further development and commercialization. To learn more, visit
www.anixa.com or follow Anixa on Twitter, LinkedIn, Facebook
and YouTube.
Forward-Looking Statements
Statements that are not historical fact may be considered
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements are not statements of historical facts, but rather
reflect Anixa's current expectations concerning future events and
results. We generally use the words "believes," "expects,"
"intends," "plans," "anticipates," "likely," "will" and similar
expressions to identify forward-looking statements. Such
forward-looking statements, including those concerning our
expectations, involve risks, uncertainties and other factors, some
of which are beyond our control, which may cause our actual
results, performance or achievements, or industry results, to be
materially different from any future results, performance, or
achievements expressed or implied by such forward-looking
statements. These risks, uncertainties and factors include, but are
not limited to, those factors set forth in "Item 1A - Risk Factors"
and other sections of our most recent Annual Report on Form 10-K as
well as in our Quarterly Reports on Form 10-Q and Current Reports
on Form 8-K. We undertake no obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by law.
You are cautioned not to unduly rely on such forward-looking
statements when evaluating the information presented in this press
release.
Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
View original
content:https://www.prnewswire.com/news-releases/anixa-biosciences-to-present-at-the-sidoti-micro-cap-virtual-conference-on-november-13--14-2024-302292348.html
SOURCE Anixa Biosciences, Inc.